Right, but for those same reasons, a Phase I trial is usually much smaller and has “safety and tolerability” as an endpoint rather than disease-related outcomes (as this one does). I don’t think those usually have randomized control groups; see the example below.
In this case, it looks like the Oxford group had previously used the same ChAdOx platform to make a MERS vaccine, and they’re leveraging that data (here: https://www.thelancet.com/journals/laninf/article/PIIS1473-3...) to move more quickly into a combined Phase I and II trial.
In this case, it looks like the Oxford group had previously used the same ChAdOx platform to make a MERS vaccine, and they’re leveraging that data (here: https://www.thelancet.com/journals/laninf/article/PIIS1473-3...) to move more quickly into a combined Phase I and II trial.